References
- Stowe J, Andrews N, Gower C, Gallagher E, Utsi L, Simmons R, Thelwall S, Tessier E, Groves N, Dabrera G, et al. Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant. KnowledgeHub [Preprint]. 2021 June 17. accessed https://khub.net/documents/135939561/479607266/Effectiveness+of+COVID-19+vaccines+against+hospital+admission+with+the+Delta+%28B.1.617.2%29+variant.pdf/1c213463-3997-ed16-2a6f-14e5deb0b997
- Borobia AM, Carcas AJ, Pérez Olmeda MT, Castaño L, Jesús Bertrán M, García-Pérez J, Campins M, Portolés A, Gonzalez-Perez M, García Morales MT, et al., CombiVacS Study Group. Reactogenicity and Immunogenicity of BNT162b2 in subjects having received a first dose of ChAdOx1s: initial results of a randomised, adaptive, phase 2 trial (CombiVacS). SSRN [Preprint]. 2021. https://ssrn.com/abstract=3854768
- Hillus D, Schwarz T, Tober-Lau P, Hastor H, Thibeault C, Kasper S, Helbig ET, Lippert LJ, Tscheak P, Schmidt ML, et al., Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1-nCoV19 and BNT162b2: a prospective cohort study. MedRxiv [Preprint]. 2021. doi:10.1101/2021.05.19.21257334.
- Groß R, Zanoni M, Seidel A, Conzelmann C, Gilg A, Krnavek D, Erdemci-Evin S, Mayer B, Hoffmann M, Pöhlmann S, et al. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity. MedRxiv [Preprint]. 2021. doi:10.1101/2021.05.30.21257971.